Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class (Ascending) Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00378-7732-05 00378-7732 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 Oct. 9, 2014 In Use
00378-7732-93 00378-7732 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 May 31, 2024 In Use
00378-7734-05 00378-7734 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 Oct. 9, 2014 In Use
00378-7734-93 00378-7734 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 May 31, 2024 In Use
00378-7734-97 00378-7734 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 May 31, 2024 In Use
68001-0517-36 68001-0517 fosaprepitant fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Aug. 23, 2021 July 31, 2024 In Use
69543-0371-10 69543-0371 Palonosetron hydrochloride Palonosetron hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 19, 2018 Jan. 31, 2026 In Use
52584-0069-00 52584-0069 ONDANSETRON ONDANSETRON 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous July 3, 2018 Nov. 30, 2023 No Longer Used
60505-6105-01 60505-6105 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 5, 2019 Nov. 30, 2023 No Longer Used
52584-0414-01 52584-0414 Metoclopramide Hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Sept. 13, 2016 May 1, 2023 No Longer Used
70860-0782-10 70860-0782 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 30, 2020 Jan. 31, 2023 No Longer Used
71288-0418-10 71288-0418 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 15, 2019 March 30, 2023 No Longer Used
16714-0248-01 16714-0248 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 28, 2023 In Use
54838-0555-50 54838-0555 Ondansetron Hydrochloride Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 27, 2011 Nov. 30, 2024 In Use
51655-0933-04 51655-0933 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 25, 2022 In Use
51655-0933-43 51655-0933 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 20, 2022 In Use
51655-0933-53 51655-0933 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 16, 2022 In Use
51655-0933-87 51655-0933 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 20, 2022 In Use
51655-0933-54 51655-0933 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 11, 2023 In Use
51655-0933-55 51655-0933 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 9, 2023 In Use
50268-0647-14 50268-0647 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 20, 2023 In Use
51655-0196-53 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 20, 2022 In Use
51655-0196-80 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 20, 2022 In Use
51655-0196-87 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 13, 2023 In Use
51655-0196-04 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 27, 2023 In Use
51662-1245-01 51662-1245 ONDANSETRON ONDANSETRON 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Sept. 23, 2018 In Use
51662-1245-03 51662-1245 ONDANSETRON ONDANSETRON 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Sept. 23, 2018 In Use
63187-0526-03 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 1, 2019 In Use
63187-0526-04 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 25, 2019 In Use
63187-0526-05 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 1, 2019 In Use
63187-0526-06 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 1, 2019 In Use
63187-0526-10 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 3, 2015 In Use
63187-0526-15 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 1, 2016 In Use
63187-0526-20 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 1, 2019 In Use
63187-0526-30 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 3, 2015 In Use
63187-0526-12 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 20, 2023 In Use
68788-9368-01 68788-9368 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 12, 2012 In Use
68788-9368-03 68788-9368 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 12, 2012 In Use
68788-9368-08 68788-9368 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 27, 2014 April 28, 2015 In Use
68788-9368-02 68788-9368 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 23, 2017 In Use
68788-9402-01 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 12, 2012 In Use
68788-9402-03 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 12, 2012 In Use
68788-9402-05 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 23, 2017 In Use
68788-9402-06 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 23, 2017 In Use
68788-9402-02 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 23, 2017 In Use
69639-0106-01 69639-0106 Fosnetupitant and Palonosetron AKYNZEO 260.0 mg/20mL, 0.28 mg/20mL Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist, Substance P/Neurokinin 1 Intravenous Aug. 1, 2023 In Use
70518-3802-00 70518-3802 ONDANSETRON Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous July 24, 2023 In Use
71288-0409-05 71288-0409 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Aug. 14, 2023 In Use
65162-0691-79 65162-0691 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 17, 2010 In Use
65162-0691-19 65162-0691 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 17, 2010 In Use
68788-8582-01 68788-8582 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 12, 2024 In Use
68788-8582-02 68788-8582 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 12, 2024 In Use
68788-8582-03 68788-8582 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 12, 2024 In Use
68788-8582-05 68788-8582 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 12, 2024 In Use
68788-8582-06 68788-8582 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 12, 2024 In Use
70518-3512-00 70518-3512 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 7, 2022 In Use
70518-3512-01 70518-3512 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 29, 2022 In Use
70518-3512-02 70518-3512 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 20, 2023 In Use
70518-3512-03 70518-3512 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 31, 2023 In Use
70518-3512-04 70518-3512 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 20, 2023 In Use
70518-3512-05 70518-3512 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 23, 2023 In Use
70518-3512-06 70518-3512 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 14, 2024 In Use
80425-0228-01 80425-0228 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 11, 2023 In Use
80425-0228-02 80425-0228 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 28, 2023 In Use
80425-0228-03 80425-0228 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 22, 2024 In Use
82650-0144-01 82650-0144 PALONOSETRON HYDROCHLORIDE Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous March 23, 2018 In Use
83634-0776-10 83634-0776 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Feb. 28, 2024 In Use
63187-0256-20 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 1, 2017 In Use
63187-0256-30 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 1, 2017 In Use
63187-0256-05 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 28, 2022 In Use
63187-0256-10 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 28, 2022 In Use
63187-0256-15 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 28, 2022 In Use
63187-0256-06 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 24, 2024 In Use
63187-0256-12 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 26, 2024 In Use
60687-0375-01 60687-0375 DRONABINOL DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic Cannabinoid Oral July 16, 2018 Sept. 30, 2025 In Use
60687-0375-21 60687-0375 DRONABINOL DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic Cannabinoid Oral March 31, 2024 In Use
43598-0305-62 43598-0305 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 19, 2013 In Use
43598-0465-62 43598-0465 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous June 19, 2015 In Use
59572-0102-01 59572-0102 Azacitidine Vidaza 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous July 5, 2004 In Use
63323-0771-39 63323-0771 Azacitidine Azacitidine 100.0 mg/30mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 16, 2017 In Use
64679-0096-01 64679-0096 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 29, 2016 In Use
68001-0313-56 68001-0313 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous July 1, 2017 In Use
00054-0271-21 00054-0271 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral July 15, 2016 In Use
00054-0272-23 00054-0272 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral July 15, 2016 In Use
00093-7473-06 00093-7473 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 7, 2014 In Use
00093-7474-89 00093-7474 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 7, 2014 In Use
16714-0467-01 16714-0467 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov. 1, 2015 In Use
16714-0468-01 16714-0468 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov. 1, 2015 In Use
55390-0115-01 55390-0115 Cladribine Cladribine Chemotherapy Antimetabolite Purine Analog Intravenous May 1, 2000 Dec. 31, 2012 No Longer Used
55390-0124-01 55390-0124 Cladribine Cladribine Chemotherapy Antimetabolite Purine Analog Intravenous Feb. 28, 2000 Dec. 31, 2012 No Longer Used
63323-0140-10 63323-0140 Cladribine Cladribine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Dec. 1, 2004 In Use
00955-1746-01 00955-1746 Clofarabine Clofarabine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous May 11, 2017 In Use
63323-0572-70 63323-0572 Clofarabine Clofarabine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous May 10, 2017 In Use
61703-0304-36 61703-0304 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Feb. 28, 1994 In Use
61703-0305-38 61703-0305 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous June 4, 1990 In Use
61703-0319-22 61703-0319 Cytarabine Cytarabine 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Nov. 22, 1999 In Use
63323-0120-20 63323-0120 Cytarabine Cytarabine 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Nov. 29, 2004 In Use
16729-0224-05 16729-0224 Decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous March 8, 2017 In Use
63323-0145-07 63323-0145 Floxuridine Floxuridine 500.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intra-arterial March 15, 2001 In Use
25021-0242-02 25021-0242 Fludarabine phosphate Fludarabine phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Oct. 15, 2016 In Use

Found 10,000 results in 13 millisecondsExport these results